CARGO Therapeutics Investor Relations Material

CARGO Therapeutics Inc. is a clinical-stage biotechnology company dedicated to advancing the next generation of chimeric antigen receptor (CAR) T-cell therapies aimed at cancer treatment. The company is focused on developing transformative CAR T-cell therapies with the mission of outsmarting cancer and delivering more cures for patients globally. By addressing the limitations of currently approved cell therapies, such as limited durability, safety concerns, and unreliable supply, CARGO Therapeutics is working on engineering CAR T-cells with genetic "cargo" designed to enhance the ability to recognize and kill cancer cells.The company is headquartered in San Carlos, California, and its shares are listed on the Nasdaq.